as 1842856 profile

5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid: inhibits Foxo1 transactivation; inhibits mRNA levels of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

AS1842856 : A quinolone that is 4-quinolone substituted at positions 1, 3, 5, 6 and 7 by ethyl, carboxy, amino, fluorine, and cyclohexylamino groups, respectively. It can directly bind to and block the transcription activity of the active forkhead box protein O1 (Foxo1), but not the Ser256-phosphorylated form. It induces cell death and growth arrest in Burkitt lymphoma cell lines at low concentrations. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	72193864
CHEMBL ID	5192734
CHEBI ID	145800
SCHEMBL ID	17387387
MeSH ID	M0552293

Synonym
5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
foxo1 inhibitor
as 1842856
as1842856
as-1842856
CHEBI:145800
836620-48-5
S8222
SCHEMBL17387387
CS-6192
HY-100596
CHEMBL5192734 ,
5-amino-7-(cyclohexyl-amino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
AKOS032945046
BCP17382
as-1842856;as 1842856
EX-A2538
BS-17713
CCG-267998
C76673
AC-36120
EN300-95548
5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
Z1270398088
bdbm50600522

Role	Description
hypoglycemic agent	A drug which lowers the blood glucose level.
anti-obesity agent	Any substance which is used to reduce or control weight.
autophagy inhibitor	Any compound that inhibits the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell).
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducer	Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
forkhead box protein O1 inhibitor	Any inhibitor that acts on forkhead box protein O1 (FOXO1).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
quinolinemonocarboxylic acid	Any aromatic carboxylic acid that contains a quinoline moiety that is substituted by one carboxy substituent.
quinolone
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
primary amino compound	A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
secondary amino compound	A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
tertiary amino compound	A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Forkhead box protein O1	Homo sapiens (human)	IC50 (µMol)	0.0330	0.0330	2.5165	5.0000	AID1892082
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of transcription by RNA polymerase II	Forkhead box protein O1	Homo sapiens (human)
blood vessel development	Forkhead box protein O1	Homo sapiens (human)
temperature homeostasis	Forkhead box protein O1	Homo sapiens (human)
intracellular glucose homeostasis	Forkhead box protein O1	Homo sapiens (human)
protein acetylation	Forkhead box protein O1	Homo sapiens (human)
autophagy	Forkhead box protein O1	Homo sapiens (human)
apoptotic process	Forkhead box protein O1	Homo sapiens (human)
DNA damage response	Forkhead box protein O1	Homo sapiens (human)
insulin receptor signaling pathway	Forkhead box protein O1	Homo sapiens (human)
cellular response to starvation	Forkhead box protein O1	Homo sapiens (human)
gene expression	Forkhead box protein O1	Homo sapiens (human)
positive regulation of autophagy	Forkhead box protein O1	Homo sapiens (human)
cellular response to insulin stimulus	Forkhead box protein O1	Homo sapiens (human)
negative regulation of stress-activated MAPK cascade	Forkhead box protein O1	Homo sapiens (human)
positive regulation of smooth muscle cell apoptotic process	Forkhead box protein O1	Homo sapiens (human)
cellular response to oxidative stress	Forkhead box protein O1	Homo sapiens (human)
positive regulation of apoptotic process	Forkhead box protein O1	Homo sapiens (human)
negative regulation of apoptotic process	Forkhead box protein O1	Homo sapiens (human)
fat cell differentiation	Forkhead box protein O1	Homo sapiens (human)
negative regulation of fat cell differentiation	Forkhead box protein O1	Homo sapiens (human)
positive regulation of gluconeogenesis	Forkhead box protein O1	Homo sapiens (human)
positive regulation of protein catabolic process	Forkhead box protein O1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Forkhead box protein O1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Forkhead box protein O1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Forkhead box protein O1	Homo sapiens (human)
negative regulation of insulin secretion	Forkhead box protein O1	Homo sapiens (human)
canonical Wnt signaling pathway	Forkhead box protein O1	Homo sapiens (human)
regulation of transcription initiation by RNA polymerase II	Forkhead box protein O1	Homo sapiens (human)
cellular response to cold	Forkhead box protein O1	Homo sapiens (human)
response to fatty acid	Forkhead box protein O1	Homo sapiens (human)
cellular response to hyperoxia	Forkhead box protein O1	Homo sapiens (human)
cellular response to nitric oxide	Forkhead box protein O1	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Forkhead box protein O1	Homo sapiens (human)
energy homeostasis	Forkhead box protein O1	Homo sapiens (human)
neuronal stem cell population maintenance	Forkhead box protein O1	Homo sapiens (human)
negative regulation of cardiac muscle hypertrophy in response to stress	Forkhead box protein O1	Homo sapiens (human)
regulation of neural precursor cell proliferation	Forkhead box protein O1	Homo sapiens (human)
regulation of reactive oxygen species metabolic process	Forkhead box protein O1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Forkhead box protein O1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
DNA-binding transcription factor activity, RNA polymerase II-specific	Forkhead box protein O1	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Forkhead box protein O1	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Forkhead box protein O1	Homo sapiens (human)
nucleic acid binding	Forkhead box protein O1	Homo sapiens (human)
chromatin binding	Forkhead box protein O1	Homo sapiens (human)
DNA-binding transcription factor activity	Forkhead box protein O1	Homo sapiens (human)
protein binding	Forkhead box protein O1	Homo sapiens (human)
beta-catenin binding	Forkhead box protein O1	Homo sapiens (human)
chromatin DNA binding	Forkhead box protein O1	Homo sapiens (human)
ubiquitin protein ligase binding	Forkhead box protein O1	Homo sapiens (human)
sequence-specific DNA binding	Forkhead box protein O1	Homo sapiens (human)
protein phosphatase 2A binding	Forkhead box protein O1	Homo sapiens (human)
promoter-specific chromatin binding	Forkhead box protein O1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Forkhead box protein O1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Forkhead box protein O1	Homo sapiens (human)
nucleus	Forkhead box protein O1	Homo sapiens (human)
nucleoplasm	Forkhead box protein O1	Homo sapiens (human)
cytoplasm	Forkhead box protein O1	Homo sapiens (human)
mitochondrion	Forkhead box protein O1	Homo sapiens (human)
cytosol	Forkhead box protein O1	Homo sapiens (human)
chromatin	Forkhead box protein O1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID1892083	Antiproliferative activity against human iPSC derived cardiomyocytes assessed as increase in cell number by measuring fold change after 3 passages at 100 nM incubated for 2 days by Hoechst staining based analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892082	Inhibition of FOXO-1 in human HepG2 cells incubated for 20 hrs by Renilla luciferase reporter gene assay	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892089	Downregulation of NPPA gene expression in human iPSC derived cardiomyocytes measured after two passages following incubation for 5 days by qRT PCR analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892093	Downregulation of MYL2 gene expression in human iPSC derived cardiomyocytes at 100 nM incubated for 5 days by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892087	Downregulation of MYH7 gene expression in human iPSC derived cardiomyocytes measured after two passages following incubation for 5 days by qRT PCR analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892091	Downregulation of ANP protein level in human iPSC derived cardiomyocytes at 100 nM incubated for 3 weeks by immunofluorescence assay	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892084	Upregulation of MYH6 gene expression in human iPSC derived cardiomyocytes at 100 nM incubated for 5 days by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892085	Upregulation of TBX2 gene expression in human iPSC derived cardiomyocytes at 100 nM incubated for 5 days by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892080	Antiproliferative activity against human iPSC derived cardiomyocytes assessed as fold increase in cell number at 100 nM incubated for 4 days without passaging by Hoechst staining based analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892094	Downregulation of NPPA gene expression in human iPSC derived cardiomyocytes at 100 nM incubated for 5 days by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892090	Downregulation of MLC2v protein level in human iPSC derived cardiomyocytes at 100 nM incubated for 3 weeks by immunofluorescence assay	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892088	Downregulation of MYL2 gene expression in human iPSC derived cardiomyocytes measured after two passages following incubation for 5 days by qRT PCR analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892092	Downregulation of MYH7 gene expression in human iPSC derived cardiomyocytes at 100 nM incubated for 5 days by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892081	Cytotoxicity against human iPSC derived cardiomyocytes at >=500 nM incubated for 4 days without passaging by Hoechst staining based analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
AID1892086	Upregulation of IRX4 gene expression in human iPSC derived cardiomyocytes aat 100 nM incubated for 5 days by qRT-PCR analysis	2022	Bioorganic & medicinal chemistry, 07-01, Volume: 65	Phenotypic screen identifies FOXO inhibitor to counteract maturation and promote expansion of human iPS cell-derived cardiomyocytes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	22 (62.86)	24.3611
2020's	13 (37.14)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (5.71%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	33 (94.29%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
pyruvic acid Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed). pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.	2.05	1	2-oxo monocarboxylic acid	cofactor; fundamental metabolite
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	2.1	1	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.41	1	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
trifluoperazine [no description available]	2.13	1	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
pirinixic acid pirinixic acid: structure	2.17	1	aryl sulfide; organochlorine compound; pyrimidines
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.1	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
carbostyril Quinolones: A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID.. quinolin-2(1H)-one : A quinolone that is 1,2-dihydroquinoline substituted by an oxo group at position 2.	6.61	33	monohydroxyquinoline; quinolone	bacterial xenobiotic metabolite
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	3.35	1	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.	2.41	1	adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate	adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.41	1	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	2.1	1	1,3-benzoxazoles; mancude organic heterobicyclic parent
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.1	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
sr141716 [no description available]	2.41	1	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
angiotensin ii, des-asp(1)-des-arg(2)-ile(5)- angiotensin II, des-Asp(1)-des-Arg(2)-Ile(5)-: 3-8 hexapeptide fragment of angiotensin II; smallest potent angiotensin II antagonist	2.31	1	organic molecular entity
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	2.31	1	amino acid zwitterion; angiotensin II	human metabolite
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.21	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	2.15	1	actinomycin	mutagen
D-fructopyranose [no description available]	2.17	1	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.1	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
bafilomycin a1 bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.	2.13	1	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
everolimus [no description available]	2.1	1	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
sb 334867-a 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea: selective OX1 receptor antagonist	2.1	1	naphthyridine derivative
cangrelor cangrelor: platelet P(2T) receptor antagonist. cangrelor : A nucleoside triphosphate analogue that is 5'-O-[({[dichloro(phosphono)methyl](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]adenosine carrying additional 2-(methylsulfanyl)ethyl and (3,3,3-trifluoropropyl)sulfanyl substituents at positions N6 and C2 respectively. Used (in the form of its tetrasodium salt) as an intravenous antiplatelet drug that prevents formation of harmful blood clots in the coronary arteries.	2.41	1	adenosine 5'-phosphate; aryl sulfide; nucleoside triphosphate analogue; organochlorine compound; organofluorine compound; secondary amino compound	P2Y12 receptor antagonist; platelet aggregation inhibitor
psammaplysene a psammaplysene A: dimeric bromotyrosine alkaloid; specific inhibitor of FOXO1a nuclear export; structure in first source	3.35	1
neuropeptide y Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.	2.41	1
glucagon-like peptide 1 Glucagon-Like Peptide 1: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.	2.41	1
divalinal-angiotensin iv divalinal-angiotensin IV: AT4 receptors antagonist	2.31	1
srt1720 [no description available]	2.21	1
peptide yy Peptide YY: A 36-amino acid peptide produced by the L cells of the distal small intestine and colon. Peptide YY inhibits gastric and pancreatic secretion.. peptide YY : A 36-membered human gut polypeptide consisting of Tyr, Pro, Ile, Lys, Pro, Glu, Ala, Pro, Gly, Glu, Asp, Ala, Ser, Pro, Glu, Glu, Leu, Asn, Arg, Tyr, Tyr, Ala, Ser, Leu, Arg, His, Tyr, Leu, Asn, Leu, Val, Thr, Arg, Gln, Arg and Tyr-NH2 residues joined in sequence.	2.41	1

Condition	Relationship Strength	Studies
Left Ventricular Dysfunction [description not available]	2.31	1
Alloxan Diabetes [description not available]	2.31	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.18	4
Cirrhosis [description not available]	2.31	1
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.31	1
Ventricular Dysfunction, Left A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.	2.31	1
Diabetic Cardiomyopathies Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.	2.69	2
Breast Cancer [description not available]	2.6	1
Astrocytoma, Grade IV [description not available]	2.6	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.6	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.6	1
Injury, Ischemia-Reperfusion [description not available]	2.25	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.25	1
Reperfusion Injury Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.	2.25	1
DDPAC [description not available]	3.17	1
Frontotemporal Dementia The most common clinical form of FRONTOTEMPORAL LOBAR DEGENERATION, this dementia presents with personality and behavioral changes often associated with disinhibition, apathy, and lack of insight.	3.17	1
Cardiac Toxicity [description not available]	2.25	1
Benign Neoplasms [description not available]	2.25	1
Atrophy Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.	2.25	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.25	1
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	2.25	1
Arthritis, Degenerative [description not available]	2.25	1
Osteoarthritis A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.	2.25	1
Diathesis [description not available]	2.25	1
Autoimmune Diabetes [description not available]	2.25	1
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	2.25	1
Diabetes Mellitus, Adult-Onset [description not available]	2.31	1
Insulin Sensitivity [description not available]	2.58	2
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.31	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.58	2
Allergic Encephalomyelitis [description not available]	2.31	1
MS (Multiple Sclerosis) [description not available]	2.31	1
Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)	2.31	1
Leukemia, Pre-B-Cell [description not available]	2.17	1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.	2.17	1
Lung Injury, Acute [description not available]	2.21	1
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	2.21	1
Muscle Relaxation That phase of a muscle twitch during which a muscle returns to a resting position.	2.21	1
Cancer of Lung [description not available]	2.21	1
Metastase [description not available]	2.21	1
Cancer of Prostate [description not available]	2.21	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.21	1
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	2.21	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.21	1
HIV Coinfection [description not available]	2.1	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	2.1	1
Pulmonary Arterial Remodeling [description not available]	2.1	1
Pulmonary Hypertension [description not available]	2.1	1
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	2.1	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	3.72	3
Complications of Diabetes Mellitus [description not available]	3.04	1
Diseases, Metabolic [description not available]	3.04	1
Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.	3.04	1
Metabolic Diseases Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)	3.04	1
Congestive Ophthalmopathy [description not available]	2.13	1
Graves Ophthalmopathy An autoimmune disorder of the EYE, occurring in patients with Graves disease. Subtypes include congestive (inflammation of the orbital connective tissue), myopathic (swelling and dysfunction of the extraocular muscles), and mixed congestive-myopathic ophthalmopathy.	2.13	1
Hyperoxia An abnormal increase in the amount of oxygen in the tissues and organs.	2.13	1
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.05	1
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.05	1

as 1842856

Description

Cross-References

Synonyms (26)

Research Excerpts

Roles (6)

Drug Classes (6)

Protein Targets (1)

Inhibition Measurements

Biological Processes (39)

Molecular Functions (14)

Ceullar Components (6)

Bioassays (15)

Research

Studies (35)

Market Indicators

Research Demand Index: 12.93

Study Types

as 1842856

Description

Cross-References

Synonyms (26)

Research Excerpts

Roles (6)

Drug Classes (6)

Protein Targets (1)

Inhibition Measurements

Biological Processes (39)

Molecular Functions (14)

Ceullar Components (6)

Bioassays (15)

Research

Studies (35)

Market Indicators

Research Demand Index: 12.93

Study Types

Related Drugs (29)

Related Conditions (59)